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INTRODUCTION
Breast cancer is the most prevalent malignancy among 
women, not only in Western countries, but also in Korea. 
More than half the newly diagnosed patients are postmeno-
pausal women, even though women younger than 50 years 
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Purpose: There are few reports from Asian countries about the 
long-term results of aromatase inhibitor adjuvant treatment for 
breast cancer. This observational study aimed to evaluate the 
long-term effects of letrozole in postmenopausal Korean women 
with operable breast cancer. Methods: Self-reported quality of life 
(QoL) scores were serially assessed for 3 years during adjuvant 
letrozole treatment using the Korean version of the Functional 
Assessment of Cancer Therapy-Breast questionnaires (version 3). 
Changes in bone mineral density (BMD) and serum cholesterol 
levels were also examined. Results: All 897 patients received the 
documented informed consent form and completed a baseline 
questionnaire before treatment. Adjuvant chemotherapy was 
administered to 684 (76.3%) subjects, and 410 (45.7%) and 396 
(44.1%) patients had stage I and II breast cancer, respectively. 
Each patient completed questionnaires at 3, 6, 12, 18, 24, 30, 
and 36 months after enrollment. Of 897 patients, 749 (83.5%) 
completed the study. The dropout rate was 16.5%. The serial trial 
outcome index, the sum of the physical and functional well-
being subscales, increased gradually and significantly from 
baseline during letrozole treatment (p<0.001). The mean serum 
cholesterol level increased significantly from 199 to 205 after 36 
months (p=0.042). The mean BMD significantly decreased from 
–0.39 at baseline to –0.87 after 36 months (p<0.001). Conclusion: 
QoL gradually improved during letrozole treatment. BMD and 
serum cholesterol level changes were similar to those in Western 
countries, indicating that adjuvant letrozole treatment is well tol-
erated in Korean women, with minimal ethnic variation.
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old comprise a relatively large proportion [1]. More than 80% 
of those who undergo treatment for breast cancer have early 
breast cancer and around 70% have hormone receptor-posi-
tive disease. Anti-estrogen treatment is preferred over cyto-
toxic chemotherapy for hormone receptor-positive breast 
cancer as identified by advanced risk assessment tools such as 
molecular profiling [2].
A number of clinical trials indicate that third-generation 
aromatase inhibitors (AI) are more effective than tamoxifen in 
reducing disease recurrence in postmenopausal women with 
hormone receptor-positive tumors [3-5]. In contrast to 
tamoxifen, AI have specific adverse effects such as osteoporo-
sis, joint pain, and change in serum lipoproteins, because of 
their estrogen-depriving function [6,7]. A number of clinical 
trials reported AI-specific adverse events; however, the major-
ity of the patients studied were not Asian. There have been 
few reports from Asian countries about the long-term results 
of adjuvant AI treatment in postmenopausal women with 
breast cancer [8,9].
The primary aim of postoperative adjuvant therapy in early 
breast cancer is prevention of disease recurrence. Safety and 
tolerability of adjuvant treatment are important considering 
the relatively lower risk of recurrence in early breast cancer.
This observational study was performed to evaluate the 
long-term effects of letrozole in postmenopausal Korean 
women with early breast cancer. We analyzed the quality of 
life (QoL) of postmenopausal women who underwent adju-
vant letrozole treatment. We also summarized the changes in 
bone mineral density (BMD) and serum cholesterol levels 
during adjuvant letrozole treatment.
METHODS
Study design and patients
Women from 30 institutes participated in this study. The 
study received institutional review board approval from indi-
vidual ethics committees of the participating institutes. All the 
women were postmenopausal with histologically proven, op-
erable, invasive breast carcinoma; had estrogen receptor-posi-
tive tumors; and were Korean. Women were eligible if they 
were at least 50 years of age and amenorrheic for at least 12 
consecutive months before letrozole treatment, if they were 
younger than 50 years old but were postmenopausal or had 
undergone a bilateral oophorectomy, or if they had postmeno-
pausal levels of follicle-stimulating hormone. 
All patients had completed primary treatment for breast 
cancer (surgery and/or systemic chemotherapy and/or radia-
tion therapy) according to the individual institutes’ treatment 
principles. Systemic chemotherapy was started within 8 weeks 
of surgery and completed within 8 weeks of entry to the study. 
Patients were excluded if the investigator believed that they 
would be unable to comply with the protocol because of psy-
chological or literacy issues.
Ethical considerations
All procedures performed in studies involving human par-
ticipants were in accordance with the ethical standards of the 
institutional and/or national research committee and with the 
1964 Helsinki declaration and its later amendments or com-
parable ethical standards. Each subject received a documented 
informed consent form to participate in the study and this 
study was approved by Institutional Review Board of Ajou 
University (Protocol No. AJIRB-CRO-07). The study is regis-
tered with ClinicalTrials.gov (number: NCT00913016).
Procedures
Each subject completed a baseline questionnaire before ad-
juvant letrozole treatment. A follow-up questionnaire was 
completed by each patient without help from a medical per-
son, before visiting their clinician 3, 6, 12, 18, 24, 30, and 36 
months after enrollment.
QoL was assessed using the Korean version of the Func-
tional Assessment of Cancer Therapy-Breast (FACT-B) ques-
tionnaire (version 3) [10]. FACT-B is a 23-item questionnaire 
that measures physical (seven items) and functional (seven 
items) well-being and includes additional subscales more spe-
cific to breast cancer (nine items). 
Outcomes
The primary endpoint of the QoL study was the trial out-
come index (TOI) of FACT-B questionnaires, which is the 
sum of the physical and functional well-being and breast can-
cer-specific subscales. The sum of TOI scores was converted 
to the mean TOI score at every visit and the changes in mean 
TOI were analyzed.
Serum total cholesterol levels were measured every 6 months 
for 3 years, while the BMD was measured every year. Subsequently, 
all these values were analyzed. 
Statistical analysis
The primary end point of the TOI was used to determine 
an appropriate sample size. It was noted that a 5-point change 
in TOI compared to the baseline was clinically relevant 
[10,11]. According to Fallowfield et al. [12] the mean TOI 
score for the primary disease group, which was similar to that 
in our study population, was 72.3 after a 3-month follow-up. 
We presumed that this mean TOI score would be maintained 
for 3 years unless adjuvant treatment was administered. 
184  Yongsik Jung, et al.
http://ejbc.kr https://doi.org/10.4048/jbc.2018.21.2.182
Meanwhile, Fallowfield et al. [13] showed that an average 3.49 
point (with an estimated standard deviation [SD] of 12.45) 
change in TOI was achieved during 2 years of follow-up in the 
tamoxifen group. Hence, we should expect an increase of 1.51 
points in the TOI with adjuvant letrozole treatment. This im-
plied that in order to achieve an average TOI score of 73.8 
rather than 72.3 with an SD of 12.45 for adjuvant therapy dur-
ing the study period, a total of 717 subjects were needed. This 
sample size would ensure at least 90% statistical power based 
on a one-sample t-test with a two-sided significance level of 
5%. Assuming a follow-up loss rate of 20%, a total of 897 pa-
tients were recruited.
The primary endpoint for QoL was analyzed using the in-
tention-to-treat (ITT) population, which included all patients 
who received at least one dose of treatment. The per-protocol 
population was used for sensitivity analysis, excluding indi-
viduals from the ITT population without any QoL and TOI 
evaluation for the baseline and final visit (at 36 months).
Patients’ demographics are summarized as mean ± SD or 
number of subjects (percentage), as appropriate. QoL scores 
were calculated for those with valid questionnaires. Changes 
in the QoL and BMD scores over the study period were as-
sessed using the generalized estimating equations (GEE) 
method to incorporate the longitudinal nature of the data. In 
subgroup analyses, QoL scores were compared between the 
chemotherapy and non-chemotherapy groups and femur and 
spine BMDs were compared between the calcium and non-
calcium groups. The Student t-test was used to compare base-
line differences between groups. Overall changes during the 
study period and linear or quadratic patterns of the trend 
were examined using GEE. The significance of the mean TOI 
score changes between the baseline and each follow-up visit 
were also examined using contrasts within the GEE model.
All analyses were conducted using SAS statistical software, 
version 9.4 (SAS Institute Inc., Cary, USA), and a p-value 
< 0.05 was considered statistically significant.
RESULTS
In total, 897 patients were enrolled and available for ITT 
analysis. Of the 897 patients, 749 (83.5%) completed the study, 
while 148 (16.5%) dropped out. The main reasons for dropout 
were loss to follow-up (35.1%), adverse events (30.4%). Other 
reasons for dropouts are described in Table 1. 
The median age of the enrolled patients was 57 years (range, 
51–79 years). The estrogen receptor was positive in 849 pa-
tients (94.6%) and the progesterone receptor was positive in 
84.4% (n = 757). The numbers of patients with stage I and 
stage II disease were 410 (45.7%) and 396 (44.1%), respective-
ly. Ninety-one patients (10.2%) had stage III disease, while 
575 women (64.1%) had node-negative disease (Table 2).
Table 1. Distribution of study subjects in the intention-to-treat popula-
tion 
Category No. (%)
Enrolled subjects 897 (100)
   Completed study 749 (83.5)
   Early dropouts 148 (16.5)
Reasons for dropouts
   Adverse events 45 (30.4)
   Abnormal laboratory tests 19 (12.9)
   Protocol violation 7 (4.7)
   Withdrawal of informed consent 18 (12.2)
   Follow-up loss 52 (35.1)
   Death 7 (4.7)
Table 2. Demographic characteristics of the study subjects (n=897)
Variable No. (%)
Age (yr)* 57.1±5.7
Estrogen receptor status
   Positive 849 (94.6)
   Negative 48 (5.4)
Progesterone receptor status 
   Positive 757 (84.4)
   Negative 140 (15.6)
Stage 
   I 410 (45.7)
   II 396 (44.1)
   III 91 (10.2)
Tumor size 
   T1 533 (59.4 )
   T2 330 (36.8)
   T3 34 (3.8)
Axillary lymph node metastasis
   N0 575 (64.1)
   N1 225 (25.1)
   N2 64 (7.1)
   N3 33 (3.7)
Adjuvant treatment 
   Radiation treatment 598 (66.7)
   Chemotherapy 684 (76.3)
Operative method
   Modified radical mastectomy 379 (42.3)
   Breast-conserving surgery 518 (57.7)
Types of adjuvant chemotherapy
Anthracycline-based treatment 
   Yes 468 (68.4)
   No 216 (31.6)
Taxane-based treatment 
   Yes 251 (36.7)
   No 487 (63.3)
Bone mineral density*
   Femur –0.21±1.07
   Spine –0.44±1.16
*Mean±SD.
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Women who had undergone breast-conserving surgery 
numbered 518 (57.7%), and 684 women (76.3%) underwent 
adjuvant chemotherapy before entry into the study. Anthracy-
cline-containing chemotherapy was administered to 468 
(68.4%) women, and 251 women (36.7%) received taxane-
based adjuvant chemotherapy.
Of the 897 women included in the analyses, 95.1% com-
pleted the questionnaire at 6 months, 92.4% at 12 months, 
87.2% at 24 months, and 79.3% at 36 months. For QoL analy-
sis, the TOI scores at each follow-up were converted to mean 
TOI scores, which were the sum of all the question scores di-
vided by the number of question items.
The mean TOI score was 2.58 at baseline, increased at the 
6-month follow-up (mean TOI, 2.63), and reached 2.78 at the 
end of the study (Table 3). The change in the TOI was statisti-
cally significant (p< 0.0001), when its trend was analyzed us-
ing GEE analysis.
The changing QoL pattern was analyzed to see whether ad-
juvant chemotherapy could affect QoL during letrozole treat-
ment. The mean TOI score was significantly lower (p =  
0.0025) in women who underwent adjuvant chemotherapy 
than in women who were at the nadir of adjuvant chemother-
apy (mean TOI, 2.55 vs. 2.68) at the beginning of the study 
(Table 3). However, the mean TOI increased more rapidly in 
women who underwent adjuvant chemotherapy before letro-
zole treatment than in women who did not (Figure 1). The 
mean TOI increased steadily and linearly in both groups. The 
increase in the mean TOI was not different between the two 
groups during letrozole treatment.
The mean BMD of long bones (femur) was –0.21 at the be-
ginning of the study and decreased steadily during the follow-
up period, reaching –0.46 36 months after enrollment (Table 
4). The decrease in the BMD of long bones with the use of le-
trozole was statistically significant (p< 0.0001) (Figure 2A). 
The findings were similar when we measured the mean spine 
BMD. It decreased from –0.44 at enrollment to –0.84 at the 
end of the study (Table 4, Figure 2B).
The change in BMD was also analyzed according to calcium 
supplement intake during the letrozole treatment. Mean BMD 
Table 3. Changes in the mean TOI score over the study period in the intention-to-treat population
Mean TOI Baseline*
Months
p-value
3 6 12 18 24 30 36
Total
   N 888 853 822 762 697 652 576 554 <0.0001†
   Mean 2.58 2.62 2.63 2.70 2.71 2.72 2.77 2.78 <0.0001‡
   SD 0.53 0.52 0.53 0.53 0.56 0.54 0.53 0.54
   p-value§ - 0.0023 0.0004 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Chemotherapy
   N 676 652 633 592 538 501 450 436 0.2039II
   Mean 2.55 2.60 2.62 2.70 2.70 2.71 2.76 2.77 0.0311¶
   SD 0.53 0.52 0.53 0.53 0.57 0.55 0.55 0.56 <0.0001‡
   p-value§ - 0.0008 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Non-chemotherapy
   N 210 199 188 168 157 149 124 115 0.0122‡
   Mean 2.68 2.69 2.69 2.71 2.74 2.77 2.82 2.84
   SD 0.51 0.52 0.52 0.53 0.53 0.53 0.49 0.48
   p-value§ - 0.8009 0.6947 0.6722 0.3305 0.0549 0.0531 0.0184
TOI= trial outcome index; SD=standard deviation. 
*p=0.0025 using Student t-test for equality of mean baseline TOI scores between the chemotherapy and non-chemotherapy groups; †For equality of mean TOI 
scores across visits using the generalized estimating equation (GEE); ‡For a linear trend test of mean TOI scores across visits using GEE analysis; §For comparisons 
of mean TOI score changes between baseline and each follow-up visit using contrasts within the GEE; IIFor an interaction effect between the chemotherapy/non-
chemotherapy group and visits using the GEE; ¶Overall equality of mean TOI scores between the chemotherapy and non-chemotherapy groups using the GEE. 
Figure 1. Comparison of mean trial outcome index (TOI) score changes 
between the chemotherapy-receiving and non-chemotherapy groups.
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Table 4. Changes in femur/spine BMD compared to the baseline in the intention-to-treat population during letrozole treatment 
BMD Baseline*
Months
p-value
12 24 36 
Femur BMD
   Total
      N 891 751 645 288 <0.0001†
      Mean –0.21 –0.38 –0.52 –0.46 <0.0001‡
      SD 1.07 1.09 1.03 0.93 0.0031§
      p-valueII - <0.0001 <0.0001 <0.0001
   Calcium
      N 165 144 134 52 0.3707¶
      Mean –0.49 –0.66 –0.88 –0.69 <0.0001**
      SD 1.12 1.13 1.02 0.97 0.0066§
      p-valueII - <0.0001 <0.0001 0.0001
   Non-calcium
      N 726 607 511 236 <0.0001‡
      Mean –0.14 –0.32 –0.43 –0.41
      SD 1.05 1.07 1.02 0.92
      p-valueII - <0.0001 <0.0001 <0.0001
Spine BMD
   Total
      N 887 752 644 286 <0.0001†
      Mean –0.44 –0.76 –0.92 –0.84 <0.0001‡
      SD 1.16 1.21 1.13 1.06 <0.0001§
      p-valueII - <0.0001 <0.0001 <0.0001
   Calcium
      N 162 145 134 51 0.1060¶
      Mean –0.79 –1.09 –1.36 –1.25 <0.0001**
      SD 1.06 1.10 0.97 1.00 0.0010§
      p-valueII - <0.0001 <0.0001 0.0001
   Non-calcium
      N 725 607 510 235 <0.0001§
      Mean –0.36 –0.69 –0.81 –0.75
      SD 1.17 1.23 1.14 1.05
      p-valueII - <0.0001 <0.0001 0.0001
BMD=bone mineral density; SD=standard deviation.  
*p=0.0001 for equality of mean baseline femur/spine BMD between the calcium and non-calcium groups using the Student t-test; †For equality of mean femur/
spine BMD across visits using the generalized estimating equation (GEE); ‡For a linear trend test of mean femur/spine BMD across visits using GEE analysis; §For a 
quadratic trend test of mean femur/spine BMD across visits using GEE analysis; IIFor comparisons of mean femur/spine BMD changes between baseline and each 
follow-up visit using contrasts within the GEE; ¶For an interaction effect between the calcium/non-calcium group and visits using the GEE; **For overall equality of 
mean femur/spine BMD between the calcium and non-calcium groups using the GEE. 
Figure 2. Changes in bone mineral density (BMD) compared to baseline with or without calcium medication during letrozole treatment. (A) Femur 
BMD. (B) Spine BMD.
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at enrollment was –0.49 in women who received calcium sup-
plements, while the mean BMD was –0.14 in women who did 
not take calcium supplements. The difference between the 
groups was statistically significant (p< 0.0001) at the begin-
ning of the study (Table 4) and was maintained until the end 
of the study (Figure 2).
Serum cholesterol for all patients was monitored annually. 
Mean total cholesterol levels increased after 12 months of le-
trozole treatment from 198 at enrollment to 203 and the in-
creasing trend was maintained until the end of the study. The 
increase was statistically significant (p= 0.0423) (Table 5).
DISCUSSION
Most clinical trials testing the clinical efficiency of AI have 
concentrated on the therapeutic superiority of AI to tamoxi-
fen [3-5]. Based on the results of large-scale clinical trials, AI 
are now the standard treatment for postmenopausal women 
with hormone receptor-positive breast cancer. In these trials, 
patients’ QoL was assessed as a subprotocol in a relatively 
small population of patients. There were no signiﬁcant differ-
ences in TOI scores over time in most large-scale clinical trials 
[13-15].
In this study, patients’ QoL significantly and continuously 
increased during letrozole treatment. This finding is some-
what different from other studies where QoL was maintained 
during AI treatment. Contrary to other studies, the TOI score 
increased during the follow-up period and the increase was 
statistically significant. This could be due to a younger popu-
lation in our study or due to an ethnic difference, since all the 
patients in this study were Korean.
In some studies, older age was a predictor of worsening 
QoL in terms of overall physical health and bodily pain 
[14,16]. In the MA.17 trial, the majority of the patients were 
older than 60 years of age, while the mean age in this study 
was about 57 years. A review of adjuvant endocrine treatment 
in elderly patients revealed that QoL is minimally affected; 
however, more long-term data may be needed [17].
Maintenance of QoL is especially important in the adjuvant 
AI treatment of postmenopausal women with early breast 
cancer. The standard treatment duration for adjuvant AI in 
hormone receptor-positive patients is currently 5 years. Com-
pliance with AI treatment is critical for an improved patient 
outcome in breast cancer. In daily practice settings, it has been 
reported that around one-third of patients failed to complete a 
5-year adjuvant tamoxifen treatment course for various rea-
sons [18]. Deterioration of QoL can affect the patients’ com-
pliance with adjuvant letrozole treatment. Of the 148 patients 
who dropped out, 40 patients discontinued the medication 
due to joint pain, although this symptom has been known to 
be associated with a better outcome [19].
A stable QoL status during letrozole treatment indicates 
that adjuvant letrozole treatment is well tolerated in post-
menopausal Korean women with breast cancer. 
During letrozole treatment in the current study, the BMD 
of the spine and femur decreased steadily. Subgroup analysis 
of the Breast International Group (BIG) 1-98 indicates that 
any type of adjuvant letrozole treatment, upfront or sequen-
tial, results in a decrease in BMD; however, BMD is not a per-
fect surrogate marker for predicting the bone fracture rate 
[20]. An association between the increased bone fracture rate 
and decreased BMD was observed in letrozole-treated pa-
tients in the BIG 1-98 trials. The MA.17 study also demon-
strated a significant decrease in lumbar spine BMD and total 
hip BMD [21]. An increased risk of bone loss and bone frac-
ture in AI-treated patients was reported in another large-scale 
clinical trial [15]. The finding was consistent with that in the 
current study. The mean spine and femur BMD decreased 
steadily in the current study. The decrease in BMD was not 
corrected by calcium supplementation. Results from the cur-
rent and other large-scale studies indicate that prophylactic 
management for bone loss such as bisphosphonate treatment 
is necessary along with adjuvant letrozole treatment, since 
zoledronic acid is reported to have a prophylactic effect on 
bone loss during adjuvant letrozole treatment [22]. A recent 
large population study demonstrated that simultaneous use of 
oral bisphosphonate can counterbalance the effect of AI-in-
duced bone loss in osteopenic and osteoporotic women [23].
We monitored serum cholesterol levels on an annual basis. 
Serum cholesterol increase did not affect the compliance of le-
trozole treatment, but the increase was statistically significant.
Complete estrogen deprivation because of letrozole is 
known to affect the serum lipid level. However, the results are 
not consistent among different studies. The National Cancer 
Institute of Canada Clinical Trial Group MA.17 lipid substudy 
Table 5. Changes of total cholesterol from baseline during letrozole 
treatment with intention-to-treat population
Total cholesterol Baseline
Months
p-value
12 24 36 
N 881 778 672 281 0.0423*
Mean (mg/dL) 198.9 202.1 201.1 203.7 0.0211†
SD (mg/dL)   35.9   35.4   35.0   31.4
p-value‡ - 0.0130 0.0391 0.0142
SD=standard deviation.  
*For an equality of mean total cholesterol across visits using generalized esti-
mating equation (GEE); †For a linear trend test of mean total cholesterol across 
visits within GEE analysis; ‡For comparisons of mean total cholesterol change 
from baseline to each of following visits using contrasts within GEE. 
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reported no remarkable changes in total cholesterol levels for 
patients treated with letrozole after 5 years of tamoxifen treat-
ment [24]. However, the frequency of hypercholesterolemia in 
patients treated with anastrozole was significantly increased 
compared to that in patients treated with tamoxifen [6]. An-
other clinical trial with Japanese postmenopausal early breast 
cancer patients reported that AI had no clinically significant 
effect on serum lipids [9]. However, the study used exemes-
tane and anastrozole, but did not include letrozole. Thus, di-
rect comparison with the current study was not feasible. 
This study has several limitations. It was an open label, sin-
gle arm study without a control group. The questionnaire re-
sults might be influenced by the patients’ community group 
or public medical information. Moreover, records of detailed 
adverse events and endocrine symptoms were missed. Despite 
these limitations, this study is meaningful in several points. It 
was performed with a considerable number of postmeno-
pausal Asian women with primary breast cancers. While most 
large-scale QoL studies have been intended for a Western 
population, this study was targeted toward Asian women to 
make a comparison based on ethnic differences.
In conclusion, QoL significantly and continuously im-
proved during letrozole treatment in postmenopausal Korean 
women with early breast cancer. The changing profiles for 
BMD and serum cholesterol levels were similar to those of 
Western countries. The results of this study indicate that adju-
vant letrozole treatment is well tolerated in Korean women, 
with minimal ethnic variation compared to Western popula-
tions.
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